Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Yuan, J and Hegde, PS and Clynes, R and Foukas, PG and Harari, A and Kleen, TO and Kvistborg, P and Maccalli, C and Maecker, HT and Page, DB and Robins, H and Song, W and Stack, EC and Wang, E and Whiteside, TL and Zhao, Y and Zwierzina, H and Butterfield, LH and Fox, BA (2016) Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 4 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© 2016 Yuan et al. The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Yuan, J
Hegde, PS
Clynes, R
Foukas, PG
Harari, A
Kleen, TO
Kvistborg, P
Maccalli, C
Maecker, HT
Page, DB
Robins, H
Song, W
Stack, EC
Wang, E
Whiteside, TL
Zhao, Y
Zwierzina, H
Butterfield, LHlhb3@pitt.eduLHB3
Fox, BA
Centers: Other Centers, Institutes, or Units > Pittsburgh Cancer Institute
Date: 19 January 2016
Date Type: Publication
Journal or Publication Title: Journal for ImmunoTherapy of Cancer
Volume: 4
Number: 1
DOI or Unique Handle: 10.1186/s40425-016-0107-3
Schools and Programs: School of Medicine > Immunology
School of Medicine > Medicine
School of Medicine > Surgery
Refereed: Yes
Article Type: Review
Date Deposited: 25 Jul 2016 17:49
Last Modified: 02 Feb 2019 14:55
URI: http://d-scholarship.pitt.edu/id/eprint/28910

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item